| N = 37 (100%) (NSAID = 17/Low-dose aspirin = 21)a |
---|---|
Indication | |
 Coronary artery disease | 11 (29.7) |
 Other cardiovascular disease | 9 (24.3) |
 Musculoskeletal disease | 15 (40.5) |
 Unknown | 3 (8.1) |
Duration | |
  < 1 month | 2 (5.4) |
 1–6 months | 11 (29.7) |
  > 6 months | 22 (59.5) |
 Unknown | 2 (5.4) |
Concurrent medication | |
 Clopidogrel | 6 (16.2) |
 Warfarin/NOAC | 7 (18.9) |
 Other anti-platelet agent | 3 (8.1) |
 None | 21 (56.8) |
Site of bleeding | |
 Small bowel | 33 (89.2) |
 Stomach | 2 (5.4) |
 Undetermined | 2 (5.4) |
Etiology of small bowel bleedingb | |
 NSAID-induced enteropathy | 25 (75.8) |
 Angioectasia | 7 (21.2) |
 Others | 1 (3.0) |
Initial management of NSAID-induced enteropathyc | |
 Discontinue NSAID/low-dose aspirin | 20 (80.0) |
 Continue NSAID/low-dose aspirin | 2 (8.0) |
+ Mucosal protective agentd | |
 Unknown | 3 (12.0) |